CN104936976B - 新颖重组博德特氏菌菌株 - Google Patents

新颖重组博德特氏菌菌株 Download PDF

Info

Publication number
CN104936976B
CN104936976B CN201380053317.5A CN201380053317A CN104936976B CN 104936976 B CN104936976 B CN 104936976B CN 201380053317 A CN201380053317 A CN 201380053317A CN 104936976 B CN104936976 B CN 104936976B
Authority
CN
China
Prior art keywords
gene
protein
pertussis
fha
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380053317.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104936976A (zh
Inventor
卡米尔·洛赫特
纳塔利·米耶尔卡雷克
哈娜·卡芒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lille University
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
University Lille Ii Droit & Sante
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Lille Ii Droit & Sante, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Lille filed Critical University Lille Ii Droit & Sante
Priority to CN201911071187.3A priority Critical patent/CN110923181A/zh
Publication of CN104936976A publication Critical patent/CN104936976A/zh
Application granted granted Critical
Publication of CN104936976B publication Critical patent/CN104936976B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201380053317.5A 2012-10-17 2013-10-17 新颖重组博德特氏菌菌株 Active CN104936976B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911071187.3A CN110923181A (zh) 2012-10-17 2013-10-17 新颖重组博德特氏菌菌株

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306279.6A EP2722338A1 (en) 2012-10-17 2012-10-17 Novel recombinant Bordetella strains
EP12306279.6 2012-10-17
PCT/EP2013/071724 WO2014060514A1 (en) 2012-10-17 2013-10-17 Novel recombinant bordetella strains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911071187.3A Division CN110923181A (zh) 2012-10-17 2013-10-17 新颖重组博德特氏菌菌株

Publications (2)

Publication Number Publication Date
CN104936976A CN104936976A (zh) 2015-09-23
CN104936976B true CN104936976B (zh) 2019-11-22

Family

ID=47073385

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380053317.5A Active CN104936976B (zh) 2012-10-17 2013-10-17 新颖重组博德特氏菌菌株
CN201911071187.3A Pending CN110923181A (zh) 2012-10-17 2013-10-17 新颖重组博德特氏菌菌株

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201911071187.3A Pending CN110923181A (zh) 2012-10-17 2013-10-17 新颖重组博德特氏菌菌株

Country Status (10)

Country Link
US (1) US9528086B2 (enExample)
EP (3) EP2722338A1 (enExample)
JP (3) JP6473086B2 (enExample)
CN (2) CN104936976B (enExample)
AU (1) AU2013333928B2 (enExample)
CA (1) CA2887055C (enExample)
DK (2) DK2909229T3 (enExample)
ES (2) ES2771675T3 (enExample)
SG (2) SG11201502010TA (enExample)
WO (1) WO2014060514A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007224734C1 (en) 2006-03-10 2016-07-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Live attenuated Bordetella strains as a single dose vaccine against whooping cough
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
DK2773371T3 (da) 2011-11-02 2020-03-09 Nat Univ Singapore Virkning af en svækket bordetella-stamme mod allergisk sygdom
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
KR101672719B1 (ko) * 2014-07-22 2016-11-04 전남대학교산학협력단 바이러스 중화항원 단백질 발현을 위한 보르데텔라 백일해 균주 및 이를 이용한 면역원성 조성물
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
AU2016248452B2 (en) * 2015-04-16 2018-05-31 Inventprise, Inc. Bordetella pertussis immunogenic vaccine compositions
DK3436034T3 (da) 2016-03-29 2025-05-12 Pasteur Institut Muterede bordetella-stammer og fremgangsmåder til brug
EP3697439A1 (en) 2017-10-18 2020-08-26 Institut Pasteur de Lille Bordetella strains expressing serotype 3 fimbriae
CN113924111A (zh) * 2019-01-04 2022-01-11 勃林格殷格翰动物保健美国公司 减毒的支气管败血性博德特菌菌株、包含该减毒的菌株的口服疫苗及其制备和使用方法
EP4196155A4 (en) 2020-08-14 2025-03-19 Iliad Biotechnologies, LLC Lyophilized live bordetella vaccines
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases
JP2023550052A (ja) * 2020-11-17 2023-11-30 イリアド バイオテクノロジーズ，リミテッド ライアビリティ カンパニー 神経変性疾患に関連する神経病理の治療および予防
CN113429188B (zh) * 2021-06-18 2022-06-10 湖北沛高环保科技有限公司 一种尾矿固废综合处理利用方法
CN116265584A (zh) * 2021-12-17 2023-06-20 远大赛威信生命科学(南京)有限公司 百日咳抗原重组表达载体及其工程菌和应用
WO2025257397A1 (en) * 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
CN118853525B (zh) * 2024-09-26 2025-01-07 上海羽冠生物技术有限公司 经修饰的百日咳鲍特菌菌株

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400783A (zh) * 2006-03-10 2009-04-01 巴斯德研究院里尔分院 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
EP1617805A4 (en) 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
WO2008058396A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
CN101790534A (zh) 2007-06-18 2010-07-28 半球生物制药公司 使用免疫活性剂的病毒感染早期干预
JP2011116659A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 組換え皮膚壊死トキソイドを含有する豚萎縮性鼻炎用薬剤
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
CA2765364C (en) 2009-06-15 2015-05-26 National University Of Singapore Influenza vaccine, composition, and methods of use
DK2773371T3 (da) 2011-11-02 2020-03-09 Nat Univ Singapore Virkning af en svækket bordetella-stamme mod allergisk sygdom
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400783A (zh) * 2006-03-10 2009-04-01 巴斯德研究院里尔分院 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e;Rui Li等;《Vaccine》;20110530;第29卷;摘要、第5502页右栏第2段、第5503页左栏第2段、第5504页左栏第3段及第5506页左栏第1段 *
Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis;Nathalie Reveneau等;《Vaccine》;20021231;第20卷;第926-933页 *

Also Published As

Publication number Publication date
US20150210978A1 (en) 2015-07-30
CN110923181A (zh) 2020-03-27
HK1213926A1 (en) 2016-07-15
EP3459966A1 (en) 2019-03-27
ES2715651T3 (es) 2019-06-05
DK2909229T3 (en) 2019-03-25
EP3459966B1 (en) 2019-11-27
ES2771675T3 (es) 2020-07-06
AU2013333928B2 (en) 2017-11-30
JP2021164481A (ja) 2021-10-14
AU2013333928A1 (en) 2015-04-09
SG10201706392YA (en) 2017-09-28
JP6473086B2 (ja) 2019-02-20
CA2887055A1 (en) 2014-04-24
JP7277516B2 (ja) 2023-05-19
EP2722338A1 (en) 2014-04-23
DK3459966T3 (da) 2020-02-17
CA2887055C (en) 2023-03-21
JP6914976B2 (ja) 2021-08-04
JP2015536134A (ja) 2015-12-21
CN104936976A (zh) 2015-09-23
JP2019088303A (ja) 2019-06-13
US9528086B2 (en) 2016-12-27
SG11201502010TA (en) 2015-04-29
EP2909229A1 (en) 2015-08-26
WO2014060514A1 (en) 2014-04-24
EP2909229B1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
CN104936976B (zh) 新颖重组博德特氏菌菌株
Hopkins et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization
Grangette et al. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum
DK1994139T3 (en) Live, attenuated Bordetella strain as a single dose vaccine against whooping cough.
Audouy et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization
Tebbey et al. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H
Wei et al. Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99
Hall et al. Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein
Olivera et al. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection
Ho et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates
Li et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e
Reveneau et al. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis
HK40003310A (en) Novel recombinant bordetella strains
HK40003310B (en) Novel recombinant bordetella strains
US20150238590A1 (en) Use of the salmonella spp type iii secretion proteins as a protective vaccination
HK1213926B (en) Novel recombinant bordetella strains
Ghorbani et al. Recombinant flagellin protein can efficiently protect mice against Salmonella typhi
CN101400783B9 (zh) 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗
WO2025257397A1 (en) Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
Guzmàn et al. Use of Salmonella Spp. Carrier Strains to Deliver Bordetella Pertussis Antigens in Mice using the oral Route
Mohit et al. Evaluation of the Effect of Promoter Type on the Immunogenicity of the Live Recombinant Salmonella Vaccines Expressing Escherichia Coli Heat-labile Enterotoxins (LTB)
Locht et al. Bordetella pertussis Highly Attenuated

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190307

Address after: France

Applicant after: Institut National de la Sante et de la Recherche Medicale

Applicant after: Pasteur Institut

Applicant after: Lille University

Address before: France

Applicant before: Institut National de la Sante et de la Recherche Medicale

Applicant before: Pasteur Institut

Applicant before: Univ Lille Ii Droit & Sante

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant